DK81691D0 - Fremgangsmaade til forhindring eller reduktion af eosinofili - Google Patents

Fremgangsmaade til forhindring eller reduktion af eosinofili

Info

Publication number
DK81691D0
DK81691D0 DK91816A DK81691A DK81691D0 DK 81691 D0 DK81691 D0 DK 81691D0 DK 91816 A DK91816 A DK 91816A DK 81691 A DK81691 A DK 81691A DK 81691 D0 DK81691 D0 DK 81691D0
Authority
DK
Denmark
Prior art keywords
eosinophilia
prevention
procedure
reduction
antagonist
Prior art date
Application number
DK91816A
Other languages
Danish (da)
English (en)
Other versions
DK81691A (da
Inventor
Robert L Coffman
Almond Avenue Los Alto Rennick
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23016493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK81691(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of DK81691D0 publication Critical patent/DK81691D0/da
Publication of DK81691A publication Critical patent/DK81691A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Optical Head (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pens And Brushes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Lubricants (AREA)
DK081691A 1988-11-03 1991-05-02 Fremgangsmaade til forhindring eller reduktion af eosinofili DK81691A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26690988A 1988-11-03 1988-11-03
PCT/US1989/004796 WO1990004979A2 (fr) 1988-11-03 1989-11-01 Procede de prevention et de reduction de l'eosinophilie

Publications (2)

Publication Number Publication Date
DK81691D0 true DK81691D0 (da) 1991-05-02
DK81691A DK81691A (da) 1991-05-02

Family

ID=23016493

Family Applications (1)

Application Number Title Priority Date Filing Date
DK081691A DK81691A (da) 1988-11-03 1991-05-02 Fremgangsmaade til forhindring eller reduktion af eosinofili

Country Status (17)

Country Link
EP (2) EP0367596B1 (fr)
JP (1) JPH07563B2 (fr)
KR (1) KR960002183B1 (fr)
AT (1) ATE98872T1 (fr)
AU (1) AU633034B2 (fr)
CA (1) CA2002144C (fr)
DE (1) DE68911653T2 (fr)
DK (1) DK81691A (fr)
ES (1) ES2062032T3 (fr)
HK (1) HK186196A (fr)
IE (1) IE63063B1 (fr)
IL (1) IL92180A (fr)
MY (1) MY107386A (fr)
NZ (1) NZ243939A (fr)
PH (1) PH26476A (fr)
WO (1) WO1990004979A2 (fr)
ZA (1) ZA898322B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG49597A1 (en) * 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
AU6000894A (en) * 1993-02-01 1994-08-29 Michel Goldman Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
ATE346867T1 (de) * 1994-12-23 2006-12-15 Smithkline Beecham Corp Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
US5683892A (en) 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
ATE435239T1 (de) 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
JP5917143B2 (ja) 2008-03-28 2016-05-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 処置方法
WO2018226339A1 (fr) 2017-06-06 2018-12-13 Glaxosmithkline Llc Compositions biopharmaceutiques et procédés pour patients pédiatriques
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856566T2 (de) * 1987-06-24 2004-06-24 Brigham And Women's Hospital, Boston Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen

Also Published As

Publication number Publication date
IL92180A (en) 1997-04-15
DE68911653T2 (de) 1994-04-07
IE63063B1 (en) 1995-03-22
WO1990004979A8 (fr) 2005-06-16
WO1990004979A2 (fr) 1990-05-17
PH26476A (en) 1992-07-27
ES2062032T3 (es) 1994-12-16
DK81691A (da) 1991-05-02
IL92180A0 (en) 1990-07-26
KR960002183B1 (ko) 1996-02-13
HK186196A (en) 1996-10-11
ZA898322B (en) 1990-11-28
NZ243939A (en) 1997-07-27
AU633034B2 (en) 1993-01-21
AU4644889A (en) 1990-05-28
EP0367596A1 (fr) 1990-05-09
JPH07563B2 (ja) 1995-01-11
IE893525L (en) 1990-05-03
EP0367596B1 (fr) 1993-12-22
JPH03505211A (ja) 1991-11-14
MY107386A (en) 1995-11-30
CA2002144C (fr) 2000-03-28
DE68911653D1 (de) 1994-02-10
CA2002144A1 (fr) 1990-05-03
ATE98872T1 (de) 1994-01-15
KR900701320A (ko) 1990-12-01
EP0441891A1 (fr) 1991-08-21

Similar Documents

Publication Publication Date Title
DK183590A (da) Fremgangsmaade til reduktion af immunoglobulin e-responser
AU4688589A (en) A method for treatment of endotoxic shock in a mammal
BR9206313A (pt) Anticorpos recombinantes para terapia humana.
FI943635A7 (fi) Ihmisen interleukiini-5:n vastaisten humanisoitujen monoklonaalisten v asta-aineiden suunnittelu, kloonaus ja ekspressio
NO864971L (no) Fremgangsmaate for fremstilling av monoklonale antistoffer som er kryssbeskyttende overfor p. aeruginosaserotyper.
DK81691A (da) Fremgangsmaade til forhindring eller reduktion af eosinofili
DK710088A (da) Fremgangsmaade til kaedestolsstrikning af flere traade
DK0504307T3 (da) Fremgangsmåde til behandling af septisk shock
FI880954A7 (fi) Seos ja menetelmä immunologista kastrointia varten.
FI92716C (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
NO890428L (no) Fremgangsmaate for fremstilling av sulfaterte alkanol- eller alkylfenol-oksetylater med redusert innhold av 1,4-dioksan.
FI924278A0 (fi) Bcrf1 antagonister foer skoetsel av epstein-barr-virusinfektioner.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment